These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23180987)

  • 1. What patients and providers should understand about economic evaluations in oncology.
    de Souza JA; de Lima Lopes G
    J Oncol Pract; 2012 Jul; 8(4):231-2. PubMed ID: 23180987
    [No Abstract]   [Full Text] [Related]  

  • 2. The new drugs advent: clinical or economic outcomes?
    De Maio E; Perrone F; Bisagni G; Boni C
    Ann Oncol; 2006 Mar; 17 Suppl 2():ii88-90. PubMed ID: 16608995
    [No Abstract]   [Full Text] [Related]  

  • 3. [Utilization of antineoplastic agents in Sweden and Europe].
    Wilking N; Jönsson B; Björn W
    Lakartidningen; 2010 Apr 21-27; 107(16):1075-80. PubMed ID: 20476705
    [No Abstract]   [Full Text] [Related]  

  • 4. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
    Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
    Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of chemotherapy in non-small-cell lung cancer.
    Saglam S; Yetis B; Ozyilkan O; Akçali Z
    J Clin Oncol; 2002 Sep; 20(17):3750-1;author reply 3751-2. PubMed ID: 12202680
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of economic evaluations of pharmacological cancer treatments in Spain between 1990 and 2010.
    Sanz-Granda A; Hidalgo A; del Llano JE; Rovira J
    Clin Transl Oncol; 2013 Jan; 15(1):9-19. PubMed ID: 23180344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost effectiveness of treatment with new agents in advanced non-small-cell lung cancer: a systematic review.
    Bongers ML; Coupé VM; Jansma EP; Smit EF; Uyl-de Groot CA
    Pharmacoeconomics; 2012 Jan; 30(1):17-34. PubMed ID: 22201521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.
    Cohen J; Looney W
    J Natl Cancer Inst; 2010 Aug; 102(15):1207; author reply 1207-10. PubMed ID: 20651322
    [No Abstract]   [Full Text] [Related]  

  • 11. Update in oncology.
    Brahmer JR
    Ann Intern Med; 2005 Oct; 143(8):587-92. PubMed ID: 16230725
    [No Abstract]   [Full Text] [Related]  

  • 12. [Cost Effectiveness and Health Economics of Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer].
    Kogure Y
    Gan To Kagaku Ryoho; 2018 May; 45(5):781-784. PubMed ID: 30026436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reply to P. Baldo et al.
    Perrone F; Di Maio M; Gallo C
    J Clin Oncol; 2015 Sep; 33(25):2826. PubMed ID: 26195706
    [No Abstract]   [Full Text] [Related]  

  • 14. Doctors less likely than patients to report toxicity of cancer treatments, study shows.
    Mayor S
    BMJ; 2015 Jan; 350():h485. PubMed ID: 25630342
    [No Abstract]   [Full Text] [Related]  

  • 15. Docetaxel in the management of breast and non-small-cell lung cancers. ASCO 2000, 22nd annual San Antonio Breast Cancer Symposium, and ECCO 10. Abstracts.
    Oncology (Williston Park); 2000 Aug; 14(8 Suppl 7):7-47. PubMed ID: 11021302
    [No Abstract]   [Full Text] [Related]  

  • 16. Side-effects of cancer drugs are under-reported in trials.
    Mayor S
    Lancet Oncol; 2015 Mar; 16(3):e107. PubMed ID: 25639368
    [No Abstract]   [Full Text] [Related]  

  • 17. Cost-effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer.
    Zhang L; Zeng X; Cai H; Li N; Liu M; Qiu L; Zheng B
    J Comp Eff Res; 2020 Dec; 9(18):1301-1309. PubMed ID: 33325265
    [No Abstract]   [Full Text] [Related]  

  • 18. Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature.
    Albaba H; Lim C; Leighl NB
    Pharmacoeconomics; 2017 Dec; 35(12):1195-1209. PubMed ID: 28861770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer.
    Ding D; Hu H; Liao M; Shi Y; She L; Yao L; Zhu Y; Zeng S; Huang J
    Adv Ther; 2020 May; 37(5):2116-2126. PubMed ID: 32193809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ixabepilone and the narrow path to developing new cytotoxic drugs.
    Gianni L
    J Clin Oncol; 2007 Aug; 25(23):3389-91. PubMed ID: 17606970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.